http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-114106200-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-03 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-56 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2510-02 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-7158 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0636 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-17 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-7051 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-17 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-85 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-62 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K19-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-10 |
| filingDate | 2021-11-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2022-07-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2022-07-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-114106200-B |
| titleOfInvention | Chimeric antigen receptor targeting CCR1 and its application |
| abstract | The present invention relates to a chimeric antigen receptor targeting CCR1 and its application, comprising a single chain antibody targeting CCR1, a hinge region, a transmembrane domain, a costimulatory domain and a signal sequentially connected from the amino terminus to the carboxyl terminus Transduction domain; the single-chain antibody targeting CCR1 includes an anti-CCR1 antibody light chain variable region and an anti-CCR1 antibody heavy chain variable region, and the amino acid sequence of the anti-CCR1 antibody light chain variable region is as shown in SEQID NO: As shown in 1, the amino acid sequence of the heavy chain variable region of the anti-CCR1 antibody is shown in SEQ ID NO: 2. The CAR-T cells constructed by using the chimeric antigen receptor targeting CCR1 of the present invention have specific targeting effect on CCR1-positive tumor cells, have significant killing effects in vitro and in vivo, can effectively remove CCR1-positive tumor cells, and are used in the field of tumor therapy. significant. |
| priorityDate | 2021-11-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 534.